1xbet 신청 Pharmaceutical Co., Ltd.

• Takeda received approval 1xbet 신청 its New Drug Application for TAKECAB^®for 1xbet 신청 treatment of acid-related diseases in Japan.
• Takeda and Otsuka executed an agreement at 1xbet 신청 end of March 2014 to co-promote TAKECAB^®in Japan. Under 1xbet 신청 agreement, 1xbet 신청 two companies will conduct informational activities for healthcare professionals with 1xbet 신청 aim of addressing unmet clinical needs in 1xbet 신청 treatment of acid-related diseases.
• At this time, Takeda will receive a milestone payment for 1xbet 신청 NDA approval. Otsuka will receive co-promotion fee based on sales amounts (in accordance with certain conditions specified in 1xbet 신청 agreement) from Takeda.

Takeda Pharmaceutical Company Limited (Head office: Chuo-ku, Osaka; President and COO: Christophe Weber; "Takeda") and Otsuka Pharmaceutical Company, Limited (Head office: Chiyoda-ku, Tokyo; President and Representative Director: Taro Iwamoto; "Otsuka") announce today that 1xbet 신청 Japanese Ministry of Health, Labour and Welfare has approved 1xbet 신청 New Drug Application submitted by Takeda ("NDA") of TAKECAB^®(generic name: Vonoprazan fumarate, hereafter "TAKECAB"), a drug for treating acid-related diseases.

TAKECAB, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits 1xbet 신청 binding of potassium ions to H⁺,K⁺-ATPase (also known as 1xbet 신청 proton pump) in 1xbet 신청 final step of gastric acid secretion in gastric parietal cells. TAKECAB provides a strong and sustained acid secretion inhibitory effect.

1xbet 신청 approval granted is based on 1xbet 신청 results of multiple Phase III clinical trials for TAKECAB in Japan. Takeda has conducted trials for indications including gastric ulcer, duodenal ulcer, reflux esophagitis andH. pylorieradication. In 1xbet 신청se trials, TAKECAB demonstrated efficacy and has a favorable profile for safety and tolerability.

Takeda and Otsuka executed an agreement at 1xbet 신청 end of March 2014 to co-promote TAKECAB in Japan. Under 1xbet 신청 agreement, Takeda will manufacture and market TAKECAB, and Takeda and Otsuka will jointly conduct informational activities for healthcare professionals. Through this partnership, 1xbet 신청 two companies aim to address issues related to 1xbet 신청 treatment of acid-related diseases and address unmet clinical needs in 1xbet 신청 gastrointestinal field.

References

About 1xbet 신청 co-promotion agreement

1xbet 신청 details of this agreement are as below:

• Takeda will receive from 1xbet 신청 an up-front payment of 20 billion yen and a milestone payment upon regulatory approval.
• Otsuka will receive from Takeda co-promotion fee based on 1xbet 신청 sales amount (based on conditions specified in 1xbet 신청 contract).
• Territory: Japan

Fur1xbet 신청r details are not disclosed.